Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-12
2011-04-12
Vogel, Nancy (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S233100
Reexamination Certificate
active
07923436
ABSTRACT:
The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the like).
REFERENCES:
patent: 5658785 (1997-08-01), Johnson
patent: 5869306 (1999-02-01), Kuma et al.
patent: 6333194 (2001-12-01), Levy et al.
patent: 7115417 (2006-10-01), Chancellor et al.
patent: 7427602 (2008-09-01), Shea et al.
patent: 2003/0053990 (2003-03-01), Rabinowitz et al.
patent: 2003/0108525 (2003-06-01), Sista et al.
patent: WO 94/29471 (1994-12-01), None
patent: WO 98/41240 (1998-09-01), None
patent: WO 98-41240 (1998-09-01), None
patent: WO 00/41731 (2000-07-01), None
patent: WO 00/43044 (2000-07-01), None
patent: WO 01/09360 (2001-02-01), None
Monahan, et al., abstract, “Stability of recombinant adeno-associated virus vectors permits delivery on implantable matrices,”Blood, 96(11 Part I): 525a (2000).
Nybert-Hofman et al., “Instability of adenoviral vectors during transport and it's implication for clinical studies,”Nature Medicine3(4): 955957 (1999).
Siemens, et al.; “Viral Vector Delivery in Solid-State Vehicles: Gene Expression in a Murine Prostate Cancer Model,”Journal of National Cancer Institute, 92(5): 403-412 (2000).
Airu et al., “Molecular bypass, the application of VEGF to gene therapy of limb ischemia;”Natl Med J China; 76: 9; 662-665 (1996). (Abstract in English only; Chinese language document.).
Qin et al., “Gene suture—a novel method for intramuscular gene transfer and its application in hypertension therapy,”Life Sciences; 65: 21; 2193-2203 (1999).
Croyle M A et al. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharmaceutical Development and Technology (Aug. 1998), vol. 3, No. 3, pp. 373-383.
Fox J L. Gene therapy clinical trials raise troubling questions. ASM News (Feb. 2000), vol. 66, No. 2, pp. 1-3.
Palú G et al. In pursuit of new developments for gene therapy of human diseases. Journal of Biotechnology (1999), vol. 68, pp. 1-13.
Siemens D R et al. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model. Journal of the National Cancer Institute (Mar. 1, 2000), vol. 92, No. 5, pp. 403-412.
Verma I M and Somia N. Gene therapy—promises, problems and prospects. Nature (Sep. 18, 1997), vol. 389, pp. 239-242.
Monahan Paul E.
Rabinowitz Joseph E.
Samulski Richard Jude
Myers Bigel Sibley & Sajovec P.A.
University of North Carolina - Chapel Hill
Vogel Nancy
LandOfFree
Methods and compounds for controlled release of recombinant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compounds for controlled release of recombinant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compounds for controlled release of recombinant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684202